2. Academic Validation
  3. Antibacterial activity of apramycin at acidic pH warrants wide therapeutic window in the treatment of complicated urinary tract infections and acute pyelonephritis

Antibacterial activity of apramycin at acidic pH warrants wide therapeutic window in the treatment of complicated urinary tract infections and acute pyelonephritis

  • EBioMedicine. 2021 Nov:73:103652. doi: 10.1016/j.ebiom.2021.103652.
Katja Becker 1,  Sha Cao 2,  Anna Nilsson 3,  Maria Erlandsson 4,  Sven-Kevin Hotop 5,  Janis Kuka 6,  Jon Hansen 7,  Klara Haldimann 1,  Solveiga Grinberga 6,  Talia Berruga-Fernández 2,  Douglas L Huseby 2,  Reza Shariatgorji 3,  Evelina Lindmark 4,  Björn Platzack 4,  Erik C Böttger 1,  David Crich 8,  Lena E Friberg 9,  Carina Vingsbo Lundberg 7,  Diarmaid Hughes 2,  Mark Brönstrup 5,  Per E Andrén 3,  Edgars Liepinsh 6,  Sven N Hobbie 10
Affiliations

Affiliations

  • 1 Institute of Medical Microbiology, University of Zurich, Gloriastrasse 30, CH-8006 Zurich, Switzerland.
  • 2 Department of Medical Biochemistry and Microbiology, Uppsala University, Box 582, 751 23 Uppsala, Sweden.
  • 3 Department of Pharmaceutical Biosciences, Uppsala University, Box 591, 751 24 Uppsala, Sweden; Science for Life Laboratory, Uppsala University, Box 591, 751 24 Uppsala, Sweden.
  • 4 RISE Research Institutes of Sweden, Forskargatan 20G, 151 36 Södertälje, Sweden.
  • 5 Helmholtz Centre for Infection Research, Inhoffenstrasse 7, D-38124 Braunschweig, Germany.
  • 6 Latvian Institute of Organic Synthesis, Aizkraukles 21, LV-1006 Riga, Latvia.
  • 7 Statens Serum Institute, Artillerivej 5, DK-2300 Copenhagen, Denmark.
  • 8 Department of Pharmaceutical and Biomedical Sciences, University of Georgia, 250 W. Green Street, Athens, GA 30602, USA.
  • 9 Department of Pharmacy, Uppsala University, Box 580, 751 23 Uppsala, Sweden.
  • 10 Institute of Medical Microbiology, University of Zurich, Gloriastrasse 30, CH-8006 Zurich, Switzerland. Electronic address: sven.hobbie@uzh.ch.
PMID: 34740109 DOI: 10.1016/j.ebiom.2021.103652
Abstract

Background: The clinical-stage drug candidate EBL-1003 (apramycin) represents a distinct new subclass of Aminoglycoside antibiotics for the treatment of drug-resistant infections. It has demonstrated best-in-class coverage of resistant isolates, and preclinical efficacy in lung Infection models. However, preclinical evidence for its utility in Other disease indications has yet to be provided. Here we studied the therapeutic potential of EBL-1003 in the treatment of complicated urinary tract Infection and acute pyelonephritis (cUTI/AP).

Methods: A combination of data-base mining, antimicrobial susceptibility testing, time-kill experiments, and four murine Infection models was used in a comprehensive assessment of the microbiological coverage and efficacy of EBL-1003 against Gram-negative uropathogens. The pharmacokinetics and renal toxicology of EBL-1003 in rats was studied to assess the therapeutic window of EBL-1003 in the treatment of cUTI/AP.

Findings: EBL-1003 demonstrated broad-spectrum activity and rapid multi-log CFU reduction against a phenotypic variety of Bacterial uropathogens including aminoglycoside-resistant clinical isolates. The basicity of amines in the apramycin molecule suggested a higher increase in positive charge at urinary pH when compared to gentamicin or amikacin, resulting in sustained drug uptake and bactericidal activity, and consequently in potent efficacy in mouse Infection models. Renal pharmacokinetics, biomarkers for toxicity, and kidney histopathology in adult rats all indicated a significantly lower nephrotoxicity of EBL-1003 than of gentamicin.

Interpretation: This study provides preclinical proof-of-concept for the efficacy of EBL-1003 in cUTI/AP. Similar efficacy but lower nephrotoxicity of EBL-1003 in comparison to gentamicin may thus translate into a higher safety margin and a wider therapeutic window in the treatment of cUTI/API.

Funding: A full list of funding bodies that contributed to this study can be found in the Acknowledgements section.

Keywords

Anti-bacterial agents; delta pH; drug uptake; efficacy; nephrotoxicity; permeability; proton-motive force; urinary tract.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z